GeneDx (WGS) Projected to Announce Quarterly Earnings on Tuesday

GeneDx (NASDAQ:WGS) is projected to announce its Q3 2026 results after the market closes on Tuesday, October 27th. Analysts expect the company to post earnings of $0.0729 per share and revenue of $122.93 million for the quarter. Individuals may visit the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Tuesday, October 27, 2026 at 8:30 AM ET.

GeneDx (NASDAQ:WGS) last announced its earnings results on Monday, August 3rd. The company reported $0.01 EPS for the quarter, topping the consensus estimate of ($0.19) by $0.20. GeneDx had a negative net margin of 23.41% and a positive return on equity of 4.12%. The firm had revenue of $114.44 million for the quarter, compared to the consensus estimate of $111.01 million. During the same period last year, the company posted $0.36 EPS. On average, analysts expect GeneDx to post ($0.41) EPS for the current fiscal year and $1.15 EPS for the next fiscal year.

GeneDx Stock Performance

Shares of WGS opened at $66.29 on Tuesday. The company has a debt-to-equity ratio of 0.40, a quick ratio of 3.06 and a current ratio of 3.30. GeneDx has a twelve month low of $32.21 and a twelve month high of $170.87. The firm’s 50 day moving average price is $81.71 and its two-hundred day moving average price is $67.38. The firm has a market cap of $1.98 billion, a P/E ratio of -18.21 and a beta of 1.95.

Insider Activity at GeneDx

In other GeneDx news, CEO Katherine Stueland sold 10,501 shares of the business’s stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $97.61, for a total value of $1,025,002.61. Following the sale, the chief executive officer owned 115,476 shares in the company, valued at approximately $11,271,612.36. The trade was a 8.34% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Kevin Feeley sold 3,728 shares of the company’s stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $97.61, for a total value of $363,890.08. Following the transaction, the chief financial officer directly owned 44,945 shares of the company’s stock, valued at approximately $4,387,081.45. This trade represents a 7.66% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 19,206 shares of company stock worth $1,808,056 in the last 90 days. Company insiders own 25.17% of the company’s stock.

Analyst Upgrades and Downgrades

WGS has been the subject of several research reports. BTIG Research reissued a “buy” rating and set a $90.00 price objective on shares of GeneDx in a research report on Tuesday, August 4th. Guggenheim boosted their price objective on shares of GeneDx from $74.00 to $83.00 and gave the company a “buy” rating in a research report on Thursday, October 1st. Weiss Ratings raised shares of GeneDx from a “sell (e+)” rating to a “sell (d)” rating in a research report on Tuesday, August 4th. Zacks Research lowered shares of GeneDx from a “strong-buy” rating to a “hold” rating in a research note on Friday, October 9th. Finally, TD Cowen reiterated a “buy” rating on shares of GeneDx in a report on Wednesday, July 15th. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $90.86.

About GeneDx

GeneDx (NASDAQ: WGS) is a precision health company that provides genetic testing and related data services. The company focuses on helping healthcare professionals identify genetic conditions, support diagnosis and treatment decisions, and better understand inherited disease.

Its offerings include exome and genome sequencing, testing for rare and undiagnosed disorders, hereditary cancer testing, and other genetic analyses. GeneDx also provides clinical interpretation and reporting intended to help physicians evaluate genetic results in the context of a patient’s symptoms and family history.

Founded in 2000, GeneDx has built a business around genomic testing for patients with rare diseases and other inherited conditions.